Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B
Table 2
Renal function and proximal renal tubular dysfunction (PRTD) at baseline and one year after discontinuation of nucleotide analogue therapy.
At baseline
At one year after drug discontinuation
P value
Serum creatinine (mg/dL)
1.1 [0.9–1.2]
1.0 [0.8–1.2]
0.023
GFR (mL/min)
61.9 [52.0–74.2]
67.3 [59.7–88.0]
0.032
Serum phosphate (mg/dL)
2.6 [2.2–3.1]
3.0 [2.7–3.3]
0.005
Serum uric acid (mg/dL)
3.5 [2.5–4.5]
4.4 [3.3–5.2]
0.002
TmPO4/GFR (mg/dL)
2.0 [1.5–2.4]
2.5 [2.3–2.6]
0.002
FE of phosphate (%)
22.9 [17.6–32.0]
15.8 [10.7–20.2]
0.005
FE of uric acid (%)
22.0 [15.3–30.0]
11.1 [7.1–15.2]
0.001
24 hour urinary protein (mg)
218.5 [153.5–414.8]
101.0 [48.0–144.0]
0.002
Urinary β2-microglobulin (mg/dL)
9,070.0 [1,655.0–41,025.0]
565.0 [252.5–2,790.0]
0.001
Data are expressed as median [interquartile range]; GFR, glomerular filtration rate; TmPO4/GFR, tubular maximal reabsorption rate of phosphate to GFR; FE, fractional excretion.
